Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
Because the combination of gemcitabine and docetaxel has shown impressive activity in soft
tissue sarcoma, we hypothesize that the addition of an antiangiogenesis agent (bevacizumab)
would enhance the anticancer activity, as shown in other tumor types.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary endpoint is overall response rate (complete and partial responses).
As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
Claire Verschraegen, MD
University of New Mexico
United States: Institutional Review Board
|New Mexico Cancer Care Associates||Santa Fe, New Mexico 87505-7670|
|University of New Mexico||Albuquerque, New Mexico 87131|
|Hematology Oncology Associates||Albuquerque, New Mexico 87106|
|St. Vincent Regional Medical Center||Santa Fe, New Mexico 87505|